Impulse control disorders in parkinson’s disease
There is an increasing awareness that impulse control disorders (ICDs), including pathologic gambling and compulsive sexual behavior, can occur as a complication of Parkinson’s disease (PD). Anecdotal experience and case reporting have suggested an association between ICDs in PD and the use of dopamine agonists. Lacking established treatments for ICDs in PD, clinical management should initially consist of modifications to or discontinuation of dopamine replacement therapy, particularly dopamine agonists. It is important that PD patients be aware that dopamine agonist use may lead to the development of an ICD, and that clinicians monitor patients as part of routine clinical care. As empirically validated treatments for ICDs are emerging, it will be important to examine their efficacy and tolerability in individuals with co-occurring PD and ICDs.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Potenza MN, Hollander E: Pathological gambling and impulse control disorders. In Neuropsychopharmacology: The 5th Generation of Progress. Edited by Coyle JT, Nemeroff CB, Charney DS, Davis KL. Baltimore, MD: Lippincott Williams & Wilkins; 2002:1725–1742.Google Scholar
- 10.Driver-Dunckley E, Samanta J, Stacy M: Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 2003, 61:422–423. The first large-scale retrospective chart review to report on the frequency and characteristics of pathologic gambling in PD, including its possible association with dopamine agonist treatment.PubMedGoogle Scholar
- 11.Dodd ML, Klos KJ, Bower JH, et al.: Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005, 62:1–5. Recent case series in PD that used formal diagnostic criteria for pathologic gambling and also suggested an association between dopamine agonist treatment, particularly pramipexole, and pathologic gambling in this population.CrossRefGoogle Scholar
- 12.Klos KJ, Bower JH, Josephs KA, et al.: Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism Related Disord 2005, 11:381–386. Recent case series reporting on the occurrence of compulsive sexual behavior in PD and its possible association with dopamine agonist treatment, suggesting that dopamine agonist treatment may be associated with the development of ICDs other than pathologic gambling in PD.CrossRefGoogle Scholar
- 16.Serrano-Dueñas M: Chronic dopamimetic drug addiction and pathologic gambling in patients with Parkinson’s disease—presentation of four cases. German J Psyhiatry 2002, 5:62–66.Google Scholar
- 21.Potenza MN, Leung HC, Blumberg HP, et al.: An fMRI Stroop task study in ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003, 160:1990–1994. This study reported decreased activity on functional MRI in the ventromedial prefrontal cortex in non-PD pathologic gamblers relative to comparison subjects when completing the Stroop paradigm, a task of response inhibition that is thought to reflect impulse control abilities.PubMedCrossRefGoogle Scholar
- 23.Reuter J, Raedler T, Rose M: Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005, 8:147–148. This study reported reduced ventral striatal (ie, the nucleus accumbens) and ventromedial prefrontal cortex activation on functional MRI in non-PD pathologic gamblers compared with control subjects when performing a simulated gambling task. In the subjects who suffered from pathologic gambling, activation of both regions was inversely correlated with gambling severity (ie, lower activation correlated with increased gambling severity).PubMedCrossRefGoogle Scholar
- 27.Levin BE, Katzen HL: Early cognitive changes and nondementing behavioral abnormalities in Parkinson’s disease. In Behavioral Neurology of Movement Disorders. Edited by Weiner WJ, Lang AE. New York: Raven Press; 1995:85–95.Google Scholar
- 29.Fuster JM: Frontal lobe syndromes. In Neuropsychiatry. Edited by Fogel BS, Schiffer RB, Rao SM. Baltimore: Williams & Wilkins; 1996:407–413.Google Scholar
- 34.Tyne HL, Medley G, Ghadiali E, Steigner MJ: Gambling in Parkinson’s disease. Mov Disord 2004, 19(Suppl 9):S195.Google Scholar
- 39.Grant JE, Potenza MN, Hollander E, et al.: Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006, 163:303–312. Recent double-blind, placebo-controlled study in pathologic gamblers without PD. The opioid antagonist nalmefene, particularly when dosed at 25 mg/d, was superior to placebo in reducing gambling-related thoughts and behaviors and decreasing patientreported disability. This study represents the largest treatment trial involving subjects with pathologic gambling that has been published to date, and supports the drug’s use in the short-term treatment of pathologic gambling.PubMedCrossRefGoogle Scholar
- 40.Hodgins DC, Petry NM: Cognitive and behavioral treatments. In Pathological Gambling: A Clinical Guide to Treatment. Edited by Grant JE, Potenza MN. Washington DC: American Psychiatric Press; 2004:169–188.Google Scholar